Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

13:53 EST 27th January 2015 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 27,000+

Tuesday 27th January 2015

FDA OKs Rockwell's iron-replacement drug for hemodialysis patients

Rockwell Medical has obtained the FDA's approval to market Triferic, or soluble ferric pyrophosphate, to maintain hemoglobin  -More- 

FDA fast-tracks hereditary angioedema drug from BioCryst Pharmaceuticals

The FDA has granted fast-track designation to BioCryst Pharmaceuticals' experimental drug BCX4161 as a treatment for heredita -More- 

Insys' ovarian cancer drug wins orphan status from FDA

Insys Therapeutics' liposomal encapsulated paclitaxel, or LEP-ETU, secured orphan-drug status from the FDA as a treatment for -More- 

Firm gains global rights to Novartis' melanoma candidate

Novartis Pharma has granted Array BioPharma the global rights to its late-stage BRAF inhibitor drug encorafenib.  -More- 

What Investors Should Do About Imminent Obesity Drug Approvals In Europe

Tax boost for ImmuPharma investors

Drug developer ImmuPharma (LON:IMM) said it expects to qualify for the Enterprise Investment Scheme, which offers a range of tax reliefs to those who invest in the stock.   The company said it had received advanced assurance from the HM Revenue ...

EIS boost for ImmuPharma

Drug developer ImmuPharma (LON:IMM) said it expects to qualify for the Enterprise Investment Scheme, which offers a range of tax reliefs to those who invest in the stock.   The company said it had received advanced assurance from the HM Revenue ...

Naurex's First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement in Depression Scores within 24 Hours in Phase 2 Study for Major Depressive Disorder

EVANSTON, Ill., Jan. 27, 2015 /PRNewswire/ -- Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that a single intravenous dose of NRX-1074 resulted in a statistically significant improvement in depression scores within 24 hours in a Phase 2 single-dose study in subjects with major depress...

Natural Healing Arts Medical Center Is Pleased to Welcome Soleve®

Soleve is a revolutionary new technique to help patients manage chronic back pain without drugs or surgery. Bradenton, Fla. (PRWEB) January 27, 2015 Now there is a revolutionary new treatment option available that is going to change the way we think about managing pain. Soleve showed 95% effectiveness in a pilot study. Soleve can contribute to making your practice the leader in back pain manage...

Destination Hope Drug and Alcohol Rehab Center Sees Admissions Increase in January

Admissions traditionally increase in January when individuals chose to get healthy. Fort Lauderdale, Fla. (PRWEB) January 27, 2015 January is traditionally a time for new year’s resolutions – many people resolve to get healthy, get fit or take better care of themselves. People suffering from drug or alcohol addiction are no different. “The first month of the year is always one of our busi...

Talcum Powder Lawsuit News Added to Attorney Website

In order to provide clear news updates on talcum powder lawsuits to the public, attorneys at the Onder Law Firm providing talcum powder lawsuit representations have expanded their website to include a news page at the Talcum Powder Ovarian Cancer Center website. St. Louis, MO (PRWEB) January 27, 2015 Attorneys providing weekly talcum powder lawsuit news updates at their Talcum Powder Ovarian Canc...

Depression Drug That Works In One Day Passes Key Test

Good drugs for depression have been around for years, but they tend to take weeks to kick in, and don’t work for everyone. Millions of people still need more help. Now a little biotech company, Naurex, is gathering data that suggests it may have a ...

European Hantavirus Diagnostics Market Tops US Market as a Result of Higher Disease Prevalence

MOUNTAIN VIEW, Calif., Jan. 27, 2015 /PRNewswire/ -- The European Hantavirus diagnostics market is growing at a compound annual growth rate (CAGR) of 5.8 percent, outperforming the U.S. market, which registered 3.7 percent. The European market is more robust primarily due to Hantavirus' high prevalence rates in Russia, Scandinavia, Finland and Belgium. However, the U.S. market has higher mortality...

Swiss drug maker Novartis posts Q4 profit drop but overall strong 2014

Swiss pharmaceutical giant Novartis AG says fourth quarter net income dropped 26 percent but the company still posted a healthy 2014 annual profit.

BRIEF-TxCell to get 1.7 mln euros for drug against Crohn's disease

* Receives 1.7 million euros ($1.9 million) from Bpifrance for Ovasave clinical development in refractory Crohn's disease

MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting on MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission

MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. today announced that an in-person meeting was held with the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health to discus...

REFILE-UPDATE 1-Novartis flags faster sales and profit growth for 2015

ZURICH, Jan 27 (Reuters) - Swiss drugmaker Novartis forecast sales and profits to grow at a faster pace this year as recent drug successes and its portfolio overhaul help it weather the impact of generic competition.

Should Hospitals Recruit Patients for Drug Company Research Projects?

I have always thought that hospitals, as stewards of abundant genotypic and phenotypic patient information, could perhaps partner with pharmaceutical companies in identifying patients for clinical research projects. A key concern of mine, however, ha...

FDA grants approval for Dexcom Share receiver

Dexcom has received approval from the US Food and Drug Administration (FDA) for its Dexcom G4 Platinum Continuous Glucose Monitoring System with Share.

Oral Cancer Is On The Rise, Are You At Risk?

PALM SPRINGS, Calif., Jan. 27, 2015 /PRNewswire-USNewswire/ -- While most other cancers are declining, oral cancer continues to rise, affecting over 43,000 Americans in 2014 alone. Due to late stage discovery, oral cancer kills one American every hour. Increased awareness and more advanced screening technologies enable early detection of oral cancer, thus increasing survival rate of those dia...

Remission Coach®: A Revolutionary Clinical Trials Platform to be Launched This Year by ICAN and MediSapiens

MOUNTAIN VIEW, California, January 27, 2015 /PRNewswire/ -- U.S.-based cancer patient advocacy and charitable organization, International Cancer Advocacy Network (ICAN), in collaboration with Finland-based bioinformatics company MediSapiens, announced their intent to launch Remission Coach® (patent pending) this year in a presentation at the Personalized Medicine World Conference in Mountain...

Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies

PETACH TIKVA, Israel, Jan. 27, 2015 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported it has received positive data regarding its CF602 drug candidate in preclinical studies conducted by a third party. CF602 was tested in an experimenta...

Bio-Techne To Host Conference Call On February 3, 2015 To Announce Second Quarter Financial Results

MINNEAPOLIS, Jan. 27, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, February 3, 2015, at 8:00 a.m. CST to review second quarter fiscal 2015 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 3, 2015 Dial-in:

BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda

RALEIGH, N.C., Jan. 27, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that it has entered into an assignment and revenue sharing agreement with Meda AB (Meda) under which Meda will transfer the marketing authorizations for ONSOLIS® (fentanyl buccal soluble film, CII) for the United States and the right to seek marketing authorizations ...

EMD Millipore Introduces New High-Performance Water Purification Systems with 24/7 Real-Time Monitoring and Remote Control

DARMSTADT, Germany, Jan. 27, 2015 /PRNewswire/ -- EMD Millipore, the Life Science business of Merck KGaA, Darmstadt, Germany, today announced the introduction of its AFS® 40E / 80E / 120E and 150E water purification systems. These new systems have been developed to provide clinical laboratories with an economical and reliable water purification solution for daily water volumes of up to 3...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks